Compare WHF & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WHF | GANX |
|---|---|---|
| Founded | 2011 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 162.5M | 159.2M |
| IPO Year | 2012 | 2021 |
| Metric | WHF | GANX |
|---|---|---|
| Price | $6.43 | $1.80 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | $7.75 | ★ $8.00 |
| AVG Volume (30 Days) | 108.4K | ★ 865.6K |
| Earning Date | 03-06-2026 | 03-26-2026 |
| Dividend Yield | ★ 16.02% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.42 | N/A |
| Revenue | ★ $76,339,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $15.23 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.39 | $1.41 |
| 52 Week High | $11.31 | $4.34 |
| Indicator | WHF | GANX |
|---|---|---|
| Relative Strength Index (RSI) | 30.81 | 32.04 |
| Support Level | $6.40 | $1.61 |
| Resistance Level | $6.83 | $2.07 |
| Average True Range (ATR) | 0.16 | 0.15 |
| MACD | -0.04 | 0.00 |
| Stochastic Oscillator | 8.30 | 5.66 |
WhiteHorse Finance Inc is a non-diversified, closed-end management investment company. It makes debt investments in privately held; small-cap companies located in United States. Its investment objective is to generate risk-adjusted returns by originating and investing in senior secured loans, including first lien and second lien facilities, to performing lower middle market companies across a range of industries.
Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Geographically, the company operates in Switzerland, Spain, the United States, and Australia.